Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

Bitar, 2009, Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006, Emerg Infect Dis, 15, 1395, 10.3201/eid1509.090334 Kontoyiannis, 2010, Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant‐associated infection Surveillance Network (TRANSNET) database, Clin Infect Dis, 50, 1091, 10.1086/651263 Pappas, 2010, Invasive fungal infections among organ transplant recipients: results of the Transplant‐associated infection Surveillance Network (TRANSNET), Clin Infect Dis, 50, 1101, 10.1086/651262 Roden, 2005, Epidemiology and outcome of zygomycosis: a review of 929 reported cases, Clin Infect Dis, 41, 634, 10.1086/432579 Chayakulkeeree, 2006, Zygomycosis: the re‐emerging fungal infection, Eur J Clin Microbiol Infect Dis, 25, 215, 10.1007/s10096-006-0107-1 Roilides, 2009, Zygomycosis in neonates: an uncommon, but life‐threatening infection, Am J Perinatol, 26, 565, 10.1055/s-0029-1220775 Marty, 2004, Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem‐cell transplants, N Engl J Med, 350, 950, 10.1056/NEJM200402263500923 Pagano, 2001, Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program, Haematologica, 86, 862 Marr, 2002, Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients, Clin Infect Dis, 34, 909, 10.1086/339202 Rees, 1998, The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population‐based laboratory active surveillance, Clin Infect Dis, 27, 1138, 10.1093/clinids/27.5.1138 Prabhu, 2004, Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment, Clin Microbiol Infect, 10, 31, 10.1111/j.1470-9465.2004.00843.x Rogers, 2008, Treatment of zygomycosis: current and new options, J Antimicrob Chemother, 61, 35, 10.1093/jac/dkm429 Gleissner, 2004, Improved outcome of zygomycosis in patients with hematological diseases?, Leuk Lymphoma, 45, 1351, 10.1080/10428190310001653691 Spellberg, 2009, Recent advances in the management of mucormycosis: from bench to bedside, Clin Infect Dis, 48, 1743, 10.1086/599105 Bialek, 2005, PCR‐based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue, J Clin Pathol, 58, 1180, 10.1136/jcp.2004.024703 De Pauw, 2008, Clin Infect Dis, 46, 1813, 10.1086/588660 Ruping, 2010, Forty‐one recent cases of invasive zygomycosis from a global clinical registry, J Antimicrob Chemother, 65, 296, 10.1093/jac/dkp430 Antoniadou, 2009, Outbreaks of zygomycosis in hospitals, Clin Microbiol Infect, 15, 55, 10.1111/j.1469-0691.2009.02982.x Pagano, 1997, Mucormycosis in patients with haematological manlignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto), Br J Haematol, 99, 331, 10.1046/j.1365-2141.1997.3983214.x Spellberg, 2005, Novel perspectives on mucormycosis: pathophysiology, presentation and management, Clin Microbiol Rev, 18, 556, 10.1128/CMR.18.3.556-569.2005 Pagano, 2004, Mucormycosis in hematologic patients, Haematologica, 89, 207 Ingram, 1989, Disseminated zygomycosis: report of four cases and review, Rev Infect Dis, 5, 741, 10.1093/clinids/11.5.741 Dannaoui, 2010, J Clin Microbiol, 48, 2043, 10.1128/JCM.02319-09 Trifilio, 2007, Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem‐cell transplants or intensive chemotherapy, Bone Marrow Transplant, 39, 425, 10.1038/sj.bmt.1705614 Lamaris, 2009, Increased virulence of zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis, J Infect Dis, 199, 1399, 10.1086/597615 Sun, 2002, In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes, Antimicrob Agents Chemother, 46, 1581, 10.1128/AAC.46.5.1581-1582.2002 Almyroudis, 2007, In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents, Antimicrob Agents Chemother, 51, 2587, 10.1128/AAC.00452-07 Dannaoui, 2003, In vitro susceptibilities of zygomycetes to conventional and new antifungals, J Antimicrob Chemother, 51, 45, 10.1093/jac/dkg020 Arikan, 2008, Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus, Med Mycol, 46, 567, 10.1080/13693780801975576 Dannaoui, 2003, Activity of posaconazole in treatment of experimental disseminated zygomycosis, Antimicrob Agents Chemother, 47, 3647, 10.1128/AAC.47.11.3647-3650.2003 Schlemmer, 2008, Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation, Bone Marrow Transplant, 42, 551, 10.1038/bmt.2008.199 Kishel, 2008, Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow‐up, J Oncol Pharm Pract, 14, 189, 10.1177/1078155208094123